Savara (SVRA) Jefferies Global Healthcare Conference 2026 summary

Company overview and product focus

• Focused on rare diseases with a single asset, MOLBREEVI, an inhaled biologic for autoimmune PAP, currently under FDA review.

• No approved therapies exist for autoimmune PAP in the US, EU, or UK; current standard is whole lung lavage, a last-resort procedure.

• $203 million cash on hand, with up to $150 million in non-dilutive financing available upon FDA approval.

• PDUFA date set for November 22, with high confidence in approval.

Market opportunity and pricing

• US addressable market estimated at 5,500 autoimmune PAP patients, based on claims and database analysis.

• Pricing expected between $400,000–$500,000 per patient per year, with strong payer coverage anticipated.

• Early launch efforts include a 23-person sales team and direct line of sight to at least 1,000 patients.

Clinical data and patient impact

• IMPALA-2 phase III trial enrolled 164 patients during COVID, with 159 completing and all entering open-label extension.

• Open-label extension showed high retention; only nine patients dropped out for non-treatment-related reasons.

• No significant safety signals or tolerability issues observed in trials.

• Early treatment in mild patients is encouraged to prevent disease progression and opportunistic infections.